(Q43241630)

17 November 2017

title

Implications of KRAS mutation status for the treatment of metastatic colorectal cancer (English)

1 reference

17 November 2017

1 reference

1

1 reference

17 November 2017

Sabine Tejpar

2

1 reference

17 November 2017

Demetris Papamichael

series ordinal

3

1 reference

17 November 2017

publication date

14 November 2009

1 reference

17 November 2017

1 reference

17 November 2017

volume

4

1 reference

17 November 2017

issue

4

1 reference

17 November 2017

page(s)

311-322

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-009-0129-6

17 November 2017

exact match

0 references

cites work

Dermatologic side effects associated with the epidermal growth factor receptor inhibitors

1 reference

12 December 2020

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

1 reference

12 December 2020

p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.

1 reference

12 December 2020

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

1 reference

12 December 2020

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients

1 reference

12 December 2020

Molecular staging of colorectal cancer: K-ras mutation analysis of lymph nodes upstages Dukes B patients

1 reference

12 December 2020

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

12 December 2020

Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

1 reference

12 December 2020

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

1 reference

12 December 2020

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

12 December 2020

Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates

1 reference

12 December 2020

Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns

1 reference

12 December 2020

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

12 December 2020

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

1 reference

12 December 2020

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

12 December 2020

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

1 reference

12 December 2020

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer

1 reference

12 December 2020

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

12 December 2020

Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study

1 reference

12 December 2020

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

12 December 2020

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

1 reference

12 December 2020

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

12 December 2020

Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK.

1 reference

12 December 2020

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

1 reference

12 December 2020

K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers

1 reference

12 December 2020

K-ras mutations in patients with early colorectal cancers

1 reference

12 December 2020

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

12 December 2020

Ki-ras gene mutations, LOH of the APC and DCC genes, and microsatellite instability in primary colorectal carcinoma are not associated with micrometastases in pericolonic lymph nodes or with patients' survival

1 reference

12 December 2020

Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number

1 reference

12 December 2020

Type and number of Ki-ras point mutations relate to stage of human colorectal cancer

1 reference

12 December 2020

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

1 reference

12 December 2020

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

12 December 2020

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

1 reference

12 December 2020

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

1 reference

12 December 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

12 December 2020

Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study

1 reference

12 December 2020

K-ras mutations in incident sporadic colorectal adenomas.

1 reference

12 December 2020

Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.

1 reference

12 December 2020

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

12 December 2020

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

12 December 2020

Genetic alterations during colorectal-tumor development

1 reference

12 December 2020

K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.

1 reference

12 December 2020

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

12 December 2020

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

12 December 2020

High frequency of K-ras mutations in sporadic colorectal adenomas

1 reference

12 December 2020

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

12 December 2020

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer

1 reference

12 December 2020

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

12 December 2020

Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?

1 reference

12 December 2020

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

12 December 2020

RAS oncogenes: the first 30 years.

1 reference

12 December 2020

Prognostic significance of K-ras mutations in colorectal carcinoma

1 reference

12 December 2020

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

12 December 2020

Detection of mutated K12-ras in histologically negative lymph nodes as an indicator of poor prognosis in stage II colorectal cancer

1 reference

12 December 2020

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

1 reference

12 December 2020

10.1007/S11523-009-0129-6

Identifiers

DOI

1 reference

17 November 2017

1 reference